Anticancer activity of methyl-substituted oxaliplatin analogs.
about
Comparative in vitro and in vivo pharmacological investigation of platinum(IV) complexes as novel anticancer drug candidates for oral application.Tumor microenvironment in focus: LA-ICP-MS bioimaging of a preclinical tumor model upon treatment with platinum(IV)-based anticancer agents.Autophagy impacts on oxaliplatin-induced hepatocarcinoma apoptosis via the IL-17/IL-17R-JAK2/STAT3 signaling pathway.Platinum-based drugs: past, present and future.Response Profiling Using Shotgun Proteomics Enables Global Metallodrug Mechanisms of Action To Be Established.Maleimide-functionalised platinum(IV) complexes as a synthetic platform for targeted drug delivery.Ruthenium(II) arene PTA (RAPTA) complexes: impact of enantiomerically pure chiral ligands.Macromolecular Pt(IV) Prodrugs from Poly(organo)phosphazenes.Influence of the Number of Axial Bexarotene Ligands on the Cytotoxicity of Pt(IV) Analogs of Oxaliplatin.Comparative studies of oxaliplatin-based platinum(iv) complexes in different in vitro and in vivo tumor models.Anticancer activity of new imidazole derivative of 1R,2R-diaminocyclohexane palladium and platinum complexes as DNA fluorescent probes.PtI2(DACH), the iodido analogue of oxaliplatin as a candidate for colorectal cancer treatment: chemical and biological features.Novel oxaliplatin derivatives with 1-(substituted benzyl)azetidine-3,3-dicarboxylate anions. Synthesis, cytotoxicity, and interaction with DNA.Gadolinium and Platinum in Tandem: Real-time Multi-Modal Monitoring of Drug Delivery by MRI and Fluorescence Imaging
P2860
Q35154374-930C1FC0-AFBA-4F2B-BDAD-8EFDDEC19E83Q35598162-35D6416A-FA8D-4685-A26E-F0452C526ACEQ37700932-0FDEA8DF-80A6-4982-931E-7D46C3B42887Q38737115-0CF3871E-EFB5-434C-A68B-20BD92E00E9EQ39029609-B5464157-D4D3-47AA-B588-08529C8899B4Q39196999-54464BCE-6456-4DAF-9CA0-8C0E20F6AFE8Q39236976-C838A90C-1790-4D5F-A2ED-78D3DD8508E4Q39773916-D197DBD9-F2AC-4ED0-A139-4FBDD0707EEAQ41212195-41F2C6F8-7C73-46FE-9BD3-ACA36D749FE6Q46417081-250BF581-EF3B-480A-8F01-5BC12781A116Q47448743-2EE70604-9746-4DCD-8087-EC8ED1C92673Q48205380-287804D0-0ADE-4EC5-9856-25DB5EF8B10AQ53636499-BBACA1F6-BF23-484A-A5A4-7DCF1D83A749Q57696711-169F2396-9DEF-4717-8E87-2D2953CA6DA6
P2860
Anticancer activity of methyl-substituted oxaliplatin analogs.
description
2012 nî lūn-bûn
@nan
2012 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Anticancer activity of methyl-substituted oxaliplatin analogs.
@ast
Anticancer activity of methyl-substituted oxaliplatin analogs.
@en
type
label
Anticancer activity of methyl-substituted oxaliplatin analogs.
@ast
Anticancer activity of methyl-substituted oxaliplatin analogs.
@en
prefLabel
Anticancer activity of methyl-substituted oxaliplatin analogs.
@ast
Anticancer activity of methyl-substituted oxaliplatin analogs.
@en
P2093
P2860
P50
P356
P1476
Anticancer activity of methyl-substituted oxaliplatin analogs.
@en
P2093
Anna K Bytzek
Dimitris N Xanthos
Johannes Gojo
Markus Galanski
Sergey A Abramkin
Wilfried Körner
P2860
P304
P356
10.1124/MOL.111.077321
P50
P577
2012-02-13T00:00:00Z